Alzheimer’s disease (AD) is a progressive neurological disease thatseriously affects older adults.1 Rivastigmine hydrogen tartrate (RHT) is applied to the treatment of AD and acts as a reversible inhibitor of anticholinesterase and butyrylcholinesterase.2 Currently, this drug is on the market for oral administration as purposes including capsule and tablet dosage forms. This evidence concerns the gene BCHE and Alzheimer disease.